From: "Don Spongberg" To:' ' < Subject: Vesselon Recent White Paper - The Need and Future Market for Noninvasive Early Stroke Therapeutics in the Urgent Setting Date: Fri, 16 Jan 2015 14:46:32 +0000 If you have trouble viewing this email, read the online version. Vesselon Recent White Paper Dear Jeffrey. I am happy to share Vesselon's recent White Paper with you. This white paper is about one of our most recent ventures — Vesselon. which is in the process of developing the world's first treatment device for stroke, the 2nd leading cause of death worldwide. The purposes of the white paper are to provide an overview of the huge limitation of the current "gold standard" and only FDA-approved stroke drug — tPA, explain how Vesselon's solution could solve the real problem, and explain why the target market of Vesselon's stroke treatment device could be as large as S4 billion. Click here to access the White Paper. Please call to learn more about how you can help Vesselon reach its goals. Sincerely, Don Spongberg Senior Managing Director Spencer Trask Ventures, Inc. Member FINR4 & SIPC 1700 E Putnam Ave, Old Greenwich, CT 06870 Phone: Download White Paper Now! The Need and Future Market for Noninvasive Early Stroke Therapeutics in the Urgent Setting EFTA00353863